Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Ltd announced the quotation of 7,441,304 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 18, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, providing stakeholders with increased liquidity and investment opportunities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company specializes in products that aim to harness the body’s immune system to fight diseases, with a particular emphasis on innovative therapies that modulate the immune response.
Average Trading Volume: 3,221,289
Technical Sentiment Signal: Sell
Current Market Cap: A$350.5M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.